Stocks · Healthcare · Biotechnology
Zymeworks Inc. ZYME
$25.15 -3.12% Close, Oct 2, 2026 · NASDAQ · Market cap $1.85B
Low risk
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -419.0% from -67.3% a year earlier.
- Revenue over the last four quarters was $37.1M, down 69.8% from a year earlier, slowing from -13.0% a quarter earlier.
- The stock is in an uptrend: above its 200-day average for 39 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 8%
- Revenue growth, 3-year CAGRBottom 4%
- Revenue growth accelerationBottom 5%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 31%
- Gross marginTop 22%
- Operating marginBottom 18%
- Accruals (lower is better)Top 43%
- Interest coverBottom 15%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 50%
- Free-cash-flow yieldBottom 45%
- EBITDA / enterprise valueBottom 45%
- Sales / enterprise valueBottom 13%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 23%
- 6-month returnBottom 40%
- 1-year return vs S&P 500Top 28%
- Distance from 52-week highTop 32%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 26%
- Upside to consensus price targetTop 49%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 32%
- Maximum drawdown, 3 yearsTop 19%
- Beta vs S&P 500 (lower is better)Top 40%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -13.0% | -69.8% | ↓ |
| Gross margin | 100.0% | 87.8% | ↓ |
| Operating margin | -67.3% | -419.0% | ↓ |
| FCF margin | -33.6% | -323.3% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -69.8% | -13.0% | ↓ | Bottom 8% |
| Gross margin | 87.8% | 100.0% | ↓ | Top 22% |
| Operating margin | -419.0% | -67.3% | ↓ | Bottom 18% |
| Net margin | -404.0% | -60.0% | ↓ | — |
| Free-cash-flow margin | -323.3% | -33.6% | ↓ | — |
| Return on invested capital | -43.7% | — | Bottom 31% | |
| Revenue growth, 3-year CAGR | -36.4% | — | Bottom 4% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -7.8%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 58.6%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +195.2 pp
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -75.3×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 7.40%
- Shareholder yield
- 7.40%
- Share count change, 1 year
- -5.7%
- Share count change, 3-year CAGR
- +2.8%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- -0.8%
- Positive 20 days after report
- 6 of 8
Analysts
- Consensus price target
- $41.00
- Target vs current price
- +63.0%
- Analysts with a rating
- 22
- Share rating Buy or Strong Buy
- 91%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | -7.9% | -1.6% | +6.1% | +32.1% | — |
| May 7, 2026 | -490.0% | -3.7% | -11.0% | -9.1% | -21.0% |
| Mar 2, 2026 | -57.1% | +0.1% | +3.4% | +3.8% | +9.1% |
| Nov 6, 2025 | +13.3% | -0.8% | +7.3% | +46.9% | +29.9% |
| Aug 7, 2025 | +105.8% | -2.0% | +12.3% | +13.5% | +54.1% |
| May 8, 2025 | +33.3% | -0.2% | -0.8% | +7.0% | +11.1% |
| Mar 5, 2025 | -3200.0% | +3.4% | -8.2% | -8.9% | -11.0% |
| Oct 31, 2024 | +2.5% | -1.2% | +12.5% | +4.0% | +5.3% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.62 | -$0.57 | -7.9% | $4.6M |
| May 7, 2026 | -$0.59 | -$0.10 | -490.0% | $2.4M |
| Mar 2, 2026 | -$0.55 | -$0.35 | -57.1% | $2.5M |
| Nov 6, 2025 | -$0.26 | -$0.30 | +13.3% | $27.6M |
| Aug 7, 2025 | $0.03 | -$0.52 | +105.8% | $48.7M |
| May 8, 2025 | -$0.30 | -$0.45 | +33.3% | $27.1M |
| Mar 5, 2025 | -$0.31 | $0.01 | -3200.0% | $31.0M |
| Oct 31, 2024 | -$0.39 | -$0.40 | +2.5% | $16.0M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (forward) | 21.9× | — | — | — |
| EV / Sales | 52.24× | — | — | Bottom 13% |
| Free-cash-flow yield | -6.49% | — | — | Bottom 45% |
| Earnings yield | -8.03% | — | — | Bottom 50% |
P/E over the past five years
Range 2.4× – 4.5× since Dec 31, 2022. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 39
- 50-day average slope (20 days)
- +3.0%
- 200-day average slope (20 days)
- +0.6%
- Distance from 50-day average
- -3.9%
- Distance from 200-day average
- +0.2%
- RSI (14)
- 40.0
- Relative volume
- 1.03×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 46.0%
- Volatility vs own 5-year history
- 42th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.96
- Correlation with S&P 500
- 0.27
- Current drawdown from 1-year high
- -19.0%
- Maximum drawdown, 3 years
- -45.7%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jan 8, 2021 | Sep 7, 2022 | -91.8% | 418 days | Not yet recovered |
| Oct 9, 2020 | Oct 30, 2020 | -16.9% | 15 days | 15 days (Nov 20, 2020) |
| Dec 4, 2020 | Dec 29, 2020 | -14.4% | 16 days | 7 days (Jan 8, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.85B
- EPS, diluted (TTM)
- -$2.02
- Revenue (TTM)
- $37.1M
- 52-week range
- $16.00 – $31.34
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $26.7M | $412.5M | $76.0M | $76.3M | $106.0M |
| Gross profit | $26.7M | $412.5M | -$67.0M | $76.3M | $106.0M |
| Operating income | -$215.6M | $130.5M | -$138.1M | -$137.1M | -$92.5M |
| Net income | -$211.8M | $124.3M | -$118.7M | -$122.7M | -$81.1M |
| EPS (diluted) | -$4.61 | $1.90 | -$1.72 | -$1.62 | -$1.08 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.0M | $31.0M | $27.1M | $48.7M | $27.6M | $2.5M | $2.4M | $4.6M |
| Net income | -$29.9M | -$23.5M | -$22.6M | $2.3M | -$19.6M | -$41.2M | -$44.2M | -$45.0M |
| EPS (diluted) | -$0.39 | -$0.31 | -$0.30 | $0.03 | -$0.26 | -$0.55 | -$0.59 | -$0.62 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$192.5M | $144.1M | -$118.3M | -$110.0M | -$33.0M |
| Capital expenditure | -$13.3M | -$13.1M | -$4.1M | -$3.1M | -$1.5M |
| Free cash flow | -$205.7M | $131.0M | -$122.4M | -$113.1M | -$34.5M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $0 | $107.5M | $76.1M | -$30.1M | -$18.4M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $270.7M
- Total assets
- $397.0M
- Total liabilities
- $316.6M
- Total debt
- $268.6M
- Net debt
- $89.2M
- Shareholders’ equity
- $80.4M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 4,939,072
- Days to cover
- 7.97
- Change vs previous report
- +4.5%
FINRA short interest, settlement date Sep 15, 2026.